Ionis Pharmaceuticals(IONS) - 2023 Q1 - Earnings Call Transcript

Onaiza Cadoret - Chief Global Product Strategy & Operations Officer Wade Walke We also continue to make really good progress in our pivotal SHTG studies of olezarsen. With donidalorsen, we're on track to complete enrollment in the Phase 2 OASIS HAE study soon, keeping us on track for data in the first half of next year. Additionally, our robust late-stage pipeline continues to expand, now at seven programs advancing in nine separate indications with the initiation of Phase 3 development of bepirovirsen in c ...